Pulmonary Arterial Hypertension Market Size Worth Around USD 10.9 BN by 2030

The global pulmonary arterial hypertension market size is predicted to be worth around USD 10.9 billion by 2030 from valued at USD 6.9 billion in 2020, growing at a CAGR of 5.1% from 2022 to 2030.

Growth Factors

Growing initiatives by key market players, high prevalence of pulmonary arterial hypertension, adoption rate, availability of reimbursement, and entry of generics are some of the key drivers of this market. As per the American Lung Association, about 500 to 1000 new PAH patients are being diagnosed every year in the U.S.

The key factors driving the market growth include the increasing prevalence of pulmonary arterial hypertension, drug development and technological advancements, product approvals, and initiatives by key companies.

Get the Sample Copy of Report@ https://www.visionresearchreports.com/report/sample/39125

The COVID-19 pandemic had a notable impact on the market. The pandemic created uncertain market conditions and lead to dampened growth. Other impacts of the pandemic include operational challenges, supply chain bottlenecks, challenges in conducting clinical trials, among others. Market players also reported a reduction in new patient starts and new patient prescriptions during 2020.

Report Coverage

By Drug Class Analysis

The prostacyclin and prostacyclin analogs segment dominated the market and accounted for the largest revenue share of around 47.0% in 2021.

The key factors contributing to the large share include a high demand and growing indications. In July 2021, Uptravi belonging to Prostacyclin and Prostacyclin Analogs segment received FDA approval for intravenous use in pulmonary arterial hypertension patients.

The SGC simulators segment is expected to grow at the fastest CAGR of over 5%. sGC stimulators can ensure maximum activation of sGC by potentiating NO-sGC signaling. 

By Type Analysis

The branded segment dominated the market and accounted for the largest revenue share of 88.2% in 2021, while the generics segment is anticipated to witness the fastest CAGR of 5.9% in the coming years.

The factors contributing to the growth include the expiry of key patents, the rising launch of generics, growing consumption in developing markets, and initiatives by major companies. 

Bayer on the other hand reported a significant increase in revenue of its branded PAH product- Adempas, driven by higher volume sales in the U.S. both in 2020 and 2021. However, the active ingredient patent of Adempas is set to expire in several key markets during the forecast period which may dampen sales in the coming years.

Enquire here Before Buying Request@ https://www.visionresearchreports.com/report/enquiry/39125

By Route of Administration Analysis

The oral segment dominated the market and held the largest revenue share of over 55.0% in 2021. This is attributable to the growing availability of oral formulations for pulmonary arterial hypertension and patient preference for the oral route of administration. 

Letairis, Opsumit, Adcirca, and Revatio are some examples of oral PAH drugs. Johnson & Johnson’s Opsumit tablets, for instance, recorded total sales of USD 1.6 billion in 2020. The sales represented a 23.5% Y-o-Y growth compared to 2019.

The intravenous/ subcutaneous segment is anticipated to register the fastest growth of over 5.0% over the forecast period due to increasing indications and approvals by regulatory agencies and advances in drug delivery systems to increase patient compliance.

By Regional Analysis

North America dominated the pulmonary arterial hypertension market and held the largest revenue share of over 42.0% in 2021. The large share is due to the developed healthcare infrastructure in the U.S. and Canada that facilitates access to advanced therapeutics.

In the Asia Pacific, the market is estimated to witness the fastest CAGR of more than 6.0% over the next few years. This is owing to the growing consumption of generics, the presence of key pharmaceutical companies, and developing healthcare infrastructure. 

Key Players

• United Therapeutics Corporation
• Bayer
• Gilead Sciences, Inc.
• Johnson & Johnson
• Viatris Inc.
• GlaxoSmithKline
• Sandoz Inc. (Novartis)
• Lupin Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries, Inc.
• Teva Pharmaceutical Industries Ltd. 

Market Segmentation

• By Drug Class 
  • Endothelin Receptor Antagonists (ERAs)
  • PDE-5 Inhibitors
  • Prostacyclin and Prostacyclin Analogs
  • SGC Stimulators
• By Type 
  • Branded
  • Generics
• By Route of Administration 
  • Oral
  • Intravenous/ subcutaneous
  • Inhalational
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Research Report@ https://www.visionresearchreports.com/report/cart/39125

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333